Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Rhodiola rosea extracts and isolated compounds and uses thereof for treating neurodegenerative diseases

A technology for neurodegenerative diseases and compounds, applied in the field of Rhodiola rosea extract and isolated compounds and their application in the treatment of neurodegenerative diseases, which can solve problems such as side effects and reduced therapeutic effect

Active Publication Date: 2014-06-11
THE HONG KONG UNIV OF SCI & TECH
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Over the years, many dopamine receptor agonists have been studied for the treatment of PD; however, after a period of treatment, the therapeutic effect decreases
And this medication, in some patients, also has side effects, such as gastrointestinal disorders and psychological cognitive problems (eg, confusion, hallucinations, psychosis, etc.)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Rhodiola rosea extracts and isolated compounds and uses thereof for treating neurodegenerative diseases
  • Rhodiola rosea extracts and isolated compounds and uses thereof for treating neurodegenerative diseases
  • Rhodiola rosea extracts and isolated compounds and uses thereof for treating neurodegenerative diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0232] Example 1 - Rhodiola rosea extract inhibits aggregation of α-synuclein protein

[0233] A total extract (TE) of Rhodiola rosea (RR) was prepared. This extract (0.07 μg) was incubated with recombinant-α-synuclein in TBS for 7 days at 37°C. After incubation, samples were filtered using Bio-Dot SF microfiltration devices (Bio Rad) according to the manufacturer's instructions. After filtration, the amount of retained α-synuclein was determined by Western blot analysis.

[0234] As shown in Figure 1, in the untreated control samples, the amount of aggregated forms of the α-synuclein protein was significantly increased at day 7 compared to day 0. Similar amounts of aggregated forms of the α-synuclein protein were found in samples treated with DMSO for 7 days when compared to untreated controls. Samples treated with Congo red, a known inhibitor against α-synuclein aggregation, were used as positive controls. Incubation of α-synuclein protein with 1 μg to 100 μg of RR’s TE ...

Embodiment 2

[0235] Example 2 - Aqueous and ethanol components of Rhodiola rosea extract inhibit aggregation of alpha-synuclein protein

[0236] Preparation of total extract (TE) and fractions of Rhodiola rosea (RR). Recombinant-α-synuclein in TBS was then incubated with the extract (μg / ml) for 7 days at 37°C. After incubation, samples were filtered with Bio-Dot SF microfiltration devices (Bio Rad) according to the manufacturer's instructions. After filtration, the amount of retained α-synuclein was determined by Western blot analysis.

[0237] RR total extract (RRTE) and RR fractions (RRPE (Rhodiola rosea petroleum ether fraction), RREA (Rhodiola rosea ethyl acetate fraction), RRBU (Rhodiola rosea butanol fraction) and RRWA (Rhodiola rosea water fraction)) was incubated with recombinant α-synuclein for 7 days. Filter cut-off assays were performed as described in Example 1. Untreated samples served as negative controls, and Congo red-treated samples served as positive controls.

[023...

Embodiment 3

[0239] Example 3 - Inhibition of α-Synuclein Protein Aggregation

[0240] Compounds RR-C20 (salidroside) and RR-C36 (rosevin) were isolated from RRWA. Then, recombinant α-synuclein in TBS was incubated with compounds RR-C20 and RR-36 for 7 days at 37°C, respectively. After incubation, samples were filtered with Bio-Dot SF microfiltration devices (Bio Rad) according to the manufacturer's instructions. After filtration, the amount of retained α-synuclein was determined by Western blot analysis.

[0241] As shown in Figure 3A, after 7 days of incubation, α-synuclein aggregates increased, and Congo red inhibited the increase in α-synuclein aggregation. RR-C36 (Rosevir) isolated from RRBU or RRWA inhibits α-synuclein aggregation in a dose-dependent manner.

[0242] Figure 3B shows that RR-C36 (rosavir) inhibits the aggregation of α-synuclein in vitro in a dose-dependent manner. The IC50 of RR-C36 anti-aggregation was -0.36 μΜ as determined by PRISM GraphPad (version 5.03).

[...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention relates to extract, fractions and isolated compound of Rhodiola rosea, and uses thereof for treating neuropathological and neurodegenerative diseases. The extracts and compounds of the present invention inhibit the aggregation of alpha-synuclein. In one embodiment, Rhodiola rosea extracts and compounds of the present invention can be used to treat synucleinopathies including PD, dementia with Lewy bodies, pure autonomic failure, multiple system atrophy, and Alzheimer's disease.

Description

[0001] CROSS REFERENCE TO RELATED APPLICATIONS This application claims the benefit of US Provisional Application Serial No. 61 / 573,022, filed August 8, 2011, which is hereby incorporated by reference in its entirety. Background technique [0002] Parkinson's disease (PD) is a disabling, progressive neurodegenerative disorder. Clinical manifestations of PD include resting tremor, rigidity, bradykinesia and postural instability with cognitive and affective impairment. The main pathological features of PD are the loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of intracytoplasmic inclusion bodies called Lewy bodies. [0003] The etiology and pathogenesis of PD have not been fully elucidated. Both environmental and genetic factors can lead to the formation of PD (Broussolle & Thobois, 2002). Most PD patients are sporadic, however some PD patients with familial inheritance of susceptibility genes have also been identified. Three missense point...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7034A61K31/7028A61K36/41A61K125/00A61P43/00A61P25/28A61P25/16A61P25/08
CPCA61K2236/39A61K31/7034A61K31/7028A61K36/41A61P25/08A61P25/16A61P25/28A61P43/00
Inventor 叶玉如叶翠芬浮光苗官可祈伍儒邦
Owner THE HONG KONG UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com